Technical Specifications

Available Stent Length (mm)	8, 13, 16, 19, 24, 29, 32, 37, 40
Available Stent Diameter (mm)	2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 4.50
Design	Uniform sinusoidal cell design
Stent Material	L605 Cobalt Chromium Stent
Foreshortening	Nearly zero
Recoil	<4%
Drug Component	Sirolimus Drug and Biodegradable Polymers
Coating Thickness	3.0 μm
Stent Strut thickness	65 μm
Balloon Delivery System	Rapid Exchange
Delivery System Usable Length	140 cm
Balloon Inflation Pressure	Nominal Pressure (NP) : 9 atm
	Rated Burst Pressure (RBP) : 16 atm (RBP for 4.5mm-14 atm)

Ordering Information

Stent Diameter (mm)	Stent Length (mm)								
	8	13	16	19	24	29	32	37	40
2.25	SU 2.2508	SU 2.2513	SU 2.2516	SU 2.2519	SU 2.2524	SU 2.2529	SU 2.2532	SU 2.2537	SU 2.2540
2.50	SU 2.5008	SU 2.5013	SU 2.5016	SU 2.5019	SU 2.5024	SU 2.5029	SU 2.5032	SU 2.5037	SU 2.5040
2.75	SU 2.7508	SU 2.7513	SU 2.7516	SU 2.7519	SU 2.7524	SU 2.7529	SU 2.7532	SU 2.7537	SU 2.7540
3.00	SU 3.0008	SU 3.0013	SU 3.0016	SU 3.0019	SU 3.0024	SU 3.0029	SU 3.0032	SU 3.0037	SU 3.0040
3.50	SU 3.5008	SU 3.5013	SU 3.5016	SU 3.5019	SU 3.5024	SU 3.5029	SU 3.5032	SU 3.5037	SU 3.5040
4.00	SU 4.0008	SU 4.0013	SU 4.0016	SU 4.0019	SU 4.0024	SU 4.0029	SU 4.0032	SU 4.0037	SU 4.0040
4.50	SU 4.5008	SU 4.5013	SU 4.5016	SU 4.5019	SU 4.5024	SU 4.5029	SU 4.5032	SU 4.5037	SU 4.5040

Nano Science for Innovative Therapies

nano THERAPEUTICS PVT. LTD.

Plot No. D-54/2, Hojiwala Industrial Estate, Road No. 23, Near Gate No. 3,
Sachin Palsana Highway, Sachin, Surat- 394 230, Gujarat, India.

T: +91 261 6450898, 6450853 F: +91 261 2392444

info@nano-therapeutics.net | sales@nano-therapeutics.net | www.nano-therapeutics.net

CE APPROVED

Superia™

Sirolimus Eluting Coronary Stent System



nano THERAPEUTICS PVT. LTD.

Superia™ The next generation Thinnest Low Injury DES design, engineered to deliver Safety & Efficacy, with the proven efficacy of Sirolimus Drug, fully biodegradable polymer and Proprietary CoCr stent surface finish.

Design Comparison of Superia

Characteristics	Endeavor Resolute	Xience	Promus Element	Superia
Strut Thickness	91 μ	81 μ	81 μ	65 μ Lower Strut Thickness
Stent Material	MP 35 N	CoCr L605	CoCr L605	CoCr L605
Coating Thickness	4.8 μ	7.8 μ	7 μ	3.0 μ Ultra Thin Coating
Polymer	Durable	Durable	Durable	Fully Biodegradable Degrades with Time & Reduces Hypersensitivity reactions
Drug	Zotaromilus	Everolimus	Everolimus	Sirolimus

Additional Design Advantages

- Superia Stent's platform has next generation uniform sinusoidal strut design offering uniform drug delivery to the vessel wall throughout stent length.
- Optimum cell size, shape and presence of straight connectors at the proximal and distal ends of the stent, reduces the stent induced stresses at the edges during expansion and thereby prevent "Edge Flaring". Hence prevent arterial injury at the edges & chances of "Edge Restenosis".
- Superia stent design consist of 'U' Connectors at ideal position that ensures low stress concentration in the longitudinal direction & allows homogenous stress distribution upon Expansion, zero foreshortening and better stent flexibility & conformability.
- Closed cell design of Superia Stent at the edges provides high radial strength which makes it suitable for Ostium Stenting.
- Superia Stent Expansion is Unidirectional, in which the force is gradually distributed along the stent length, this prevents arterial injuries during stent expansion and chances of restenosis are lower.

Drug Release Kinetics

Superia has proven drug release kinetics. Initial burst release of Sirolimus followed by sustained release up to 40 days.



Excellent Uniform Sirolimus Drug Coating



250 X Magnification



400 X Magnification

SEM Images of Superia Stents.

Superia PMS Study shows Excellent Results

No. of Patients	200 Patients
No. of Patients completed 365 days of follow up	180 patients
No. of Patients completed 180 days Angiographic follow up	50 patients
Interim Endpoint analysis: 365 Days Follow up in 175 patients	
MACE: (Cardiac Death, MI, TLR)	3 (1.7%)
Cardiac Death	1 (0.57%)
MI	0 (0%)
TLR	2 (1.14%)
Device Malfunction	0 (0%)
Procedural Success	100 %
Co Primary End Point Analysis: 180 Days Angiographic Follow up – In 50 Patients	
Late Lumen Loss at 180 Days	
In Stent	0.10 mm
In Segment	0.14 mm

1.7% MACE at 365 days 175 patients